REG - Advanced Oncotherapy - Result of AGM

Advanced OncotherapyAnnouncement

29/07/2022 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220729:nRSc3240Ua&default-theme=true

RNS Number : 3240U  Advanced Oncotherapy PLC  29 July 2022

29 July 2022

 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Result of AGM

 

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, announces that at the Annual
General Meeting (AGM) held earlier today, all resolutions were passed. The
results of the proxy voting for the AGM are set out below:

 

 Resolution                                                                      Total votes For(1)  % of votes cast(2)  Total Votes Against  % of votes cast(2)  Votes Withheld(3)
 1. To receive the audited financial statements and the Auditor's and Directors  186,380,372         88.84               23,401,405           11.16               8,237
 reports for the year ended 31 December 2021
 2. To re-appoint Michael Bradfield as a Director of the Company                 209,005,437         99.63               777,004              0.37                7,573
 3. To re-appoint Hans von Celsing as a Director of the Company                  186,340,437         88.84               23,402,004           11.16               7,573
 4. To re-appoint Lori Cross as a Director of the Company                        208,965,437         99.63               777,004              0.37                7,573
 5. To re-appoint Prof. Steve Myers as a Director of the Company                 209,005,437         99.63               777,004              0.37                7,573
 6. To re-appoint Dr Nick Plowman as a Director of the Company                   208,965,437         99.63               777,004              0.37                7,573
 7. To re-appoint Nicolas Serandour as a Director of the Company                 208,965,437         99.63               777,004              0.37                7,573
 8. To re-appoint Dr Michael Sinclair as a Director of the Company               209,005,437         99.63               777,170              0.37                7,407
 9. To re-appoint Dr Enrico Vanni as a Director of the Company                   186,340,437         88.84               23,402,004           11.16               7,573
 10. To re-appoint Renhua Zhang as a Director of the Company                     208,965,437         99.63               777,004              0.37                7,573
 11. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company             178,595,773         85.13               31,186,834           14.87               7,407
 12. To authorise the Directors to determine the remuneration of the Auditors    208,998,603         99.63               781,504              0.37                9,907
 13. That the Directors be authorised to allot shares and/or to grant rights to  208,778,437         99.52               1,001,670            0.48                9,907
 subscribe for, or to convert any securities into shares in the Company
 14. That, subject to Resolution 13, the Directors be empowered to allot equity  186,025,264         88.68               23,754,677           11.32               9,907
 securities as if section 561 of the Act did not apply

 

Notes

 

1.   Any proxy votes that were at the discretion of the Chairman are
included in the "Total Votes For" each resolution

2.   Percentage of votes cast excludes Votes Withheld

3.   Votes Withheld are not votes in law and do not count in the number of
votes counted for or against a resolution

 

- ENDS -

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Liz Kirchner (Corporate Finance)           Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEMFIUEESEEW